{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:18:01Z","timestamp":1783678681760,"version":"3.55.0"},"reference-count":118,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Nanotechnology is rapidly advancing as a promising approach in ovarian cancer management, addressing key challenges such as late diagnosis, drug resistance, and systemic toxicity of conventional therapies. Nanoparticles\u2014engineered at the 1\u2013100 nm scale\u2014possess unique physical and biological properties that make them well-suited for targeted drug delivery, imaging, and biomarker detection. In diagnostics, platforms such as gold nanoparticles, quantum dots, superparamagnetic iron oxide nanoparticles (SPIONs), and carbon-based nanomaterials have demonstrated the ability to improve sensitivity and specificity, enabling the detection of low-abundance biomarkers and enhancing imaging contrast. These advances could significantly improve the early-stage detection, where survival outcomes are most favorable. Therapeutically, nanoparticles offer controlled and sustained drug release, targeted delivery to specific tumor sites, and the ability to co-deliver multiple agents, including siRNA and mRNA, in order to overcome resistance pathways. Clinically, liposomal formulations such as Doxil, already demonstrate reduced toxicity and improved drug bioavailability, while polymeric, silica, gold, and magnetic nanoparticles continue to show encouraging results in preclinical and early clinical studies. Although challenges remain\u2014including large-scale production, long-term safety evaluation, and regulatory complexity\u2014the current body of evidence highlights nanotechnology\u2019s transformative potential in ovarian cancer care. By enabling earlier detection, more precise targeting, and reduced systemic toxicity, nanomedicine represents a critical step toward improving both survival and quality of life in affected patients.<\/jats:p>","DOI":"10.3390\/cells15141248","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:46:47Z","timestamp":1783676807000},"page":"1248","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanotechnology in Ovarian Cancer: Advances in Early Diagnosis and Targeted Therapy to Enhance Patient Quality of Life"],"prefix":"10.3390","volume":"15","author":[{"given":"Andreea","family":"Moise-Crintea","sequence":"first","affiliation":[{"name":"Department of Molecular Sciences, University of Medicine and Pharmacy \u201cIuliu Ha\u021bieganu\u201d, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiberiu Vasile Ioan","family":"Nistor","sequence":"additional","affiliation":[{"name":"Department of Molecular Sciences, University of Medicine and Pharmacy \u201cIuliu Ha\u021bieganu\u201d, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7597-823X","authenticated-orcid":false,"given":"Nadica","family":"Motofelea","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Department of Clinical Practical Skills, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru Catalin","family":"Motofelea","sequence":"additional","affiliation":[{"name":"Centre for Molecular Research in Nephrology and Vascular Disease\/MOL-NEPHRO-VASC, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-1287","authenticated-orcid":false,"given":"Liliana Ana","family":"Tuta","sequence":"additional","affiliation":[{"name":"Nephrology Department, Faculty of Medicine, \u201cOvidius\u201d University of Constanta, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minodora","family":"Manea","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Iuliu Ha\u021bieganu University of Medicine and Pharmacy, 400023 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Joseph, T.M., Mahapatra, D.K., Esmaeili, A., Piszczyk, \u0141., Hasanin, M.S., Kattali, M., Haponiuk, J., and Thomas, S. (2023). Nanoparticles: Taking a Unique Position in Medicine. Nanomaterials, 13.","DOI":"10.3390\/nano13030574"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5114\/bta.2024.141807","article-title":"Nanotechnology in cancer therapeutics, diagnosis, and management","volume":"105","author":"Hazarika","year":"2024","journal-title":"BioTechnologia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"eaba5379","DOI":"10.1126\/sciadv.aba5379","article-title":"Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome","volume":"6","author":"Hossen","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zhang, J., Ding, H., Zhang, F., Xu, Y., Liang, W., and Huang, L. (2023). New trends in diagnosing and treating ovarian cancer using nanotechnology. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1160985"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.22270\/ijmspr.v8i4.50","article-title":"A Review on Nanotechnology in Cancer Diagnosis and Therapy: It\u2019s Application","volume":"8","author":"Purohit","year":"2022","journal-title":"Int. J. Med. Sci. Pharma Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1515\/ntrev-2013-0013","article-title":"Nanotechnology for cancer treatment","volume":"3","author":"Gmeiner","year":"2014","journal-title":"Nanotechnol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/ijc.27909","article-title":"Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial","volume":"132","author":"Pinsky","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_8","first-page":"3231","article-title":"Identification of six serum antigens and autoantibodies for the detection of early stage epithelial ovarian carcinoma by bioinformatics analysis and liquid chip analysis","volume":"16","author":"Zou","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1002\/sim.8731","article-title":"Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies","volume":"39","author":"Han","year":"2020","journal-title":"Stat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1158\/0008-5472.CAN-13-1550","article-title":"Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/onc.2016.197","article-title":"Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: A potential therapeutic target","volume":"36","author":"Saini","year":"2016","journal-title":"Oncogene"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1158\/1535-7163.MCT-14-0135","article-title":"Expression of the miR200 Family of microRNAs in Mesothelial Cells Suppresses the Dissemination of Ovarian Cancer Cells","volume":"13","author":"Sugiyama","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ygyno.2015.06.005","article-title":"Long-term mortality among women with epithelial ovarian cancer","volume":"138","author":"Dinkelspiel","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/0008-5472.CAN-19-1601","article-title":"Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis","volume":"80","author":"Asem","year":"2020","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"s12","DOI":"10.1136\/ijgc-2019-000666","article-title":"Tumor microenvironment and immunology of ovarian cancer: 12th Biennial Rivkin Center Ovarian Cancer Research Symposium","volume":"29","author":"Mitra","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/1878-0261.12046","article-title":"Gene regulatory networking reveals the molecular cue to lysophosphatidic acid-induced metabolic adaptations in ovarian cancer cells","volume":"11","author":"Ray","year":"2017","journal-title":"Mol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/709049","article-title":"Early Detection Biomarkers for Ovarian Cancer","volume":"2012","author":"Sarojini","year":"2012","journal-title":"J. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mco2.6","article-title":"Metabolism in tumor microenvironment: Implications for cancer immunotherapy","volume":"1","author":"Shi","year":"2020","journal-title":"MedComm"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3892\/mco.2014.470","article-title":"Advances in the application of nanotechnology in the diagnosis and treatment of gastrointestinal tumors","volume":"3","author":"Sun","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., and Mozafari, M.R. (2018). Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10020057"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Shi, J., Huo, R., Li, N., Li, H., Zhai, T., Li, H., Shen, B., Ye, J., Fu, R., and Di, W. (2019). CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6321-x"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"106731","DOI":"10.1016\/j.reactfunctpolym.2026.106731","article-title":"Progress in biopolymer-based polyelectrolyte complexes for biomedical applications","volume":"224","author":"Bhattacharyya","year":"2026","journal-title":"React. Funct. Polym."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13148-022-01285-9","article-title":"Detection of ovarian cancer using plasma cell-free DNA methylomes","volume":"14","author":"Lu","year":"2022","journal-title":"Clin. Epigenet."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Gerosa, C., Crisponi, G., Nurchi, V.M., Saba, L., Cappai, R., Cau, F., Faa, G., Van Eyken, P., Scartozzi, M., and Floris, G. (2020). Gold Nanoparticles: A New Golden Era in Oncology?. Pharmaceuticals, 13.","DOI":"10.3390\/ph13080192"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"012067","DOI":"10.1088\/1742-6596\/3008\/1\/012067","article-title":"Advances in the application of gold nanoparticles in cancer diagnosis and treatment","volume":"3008","author":"Song","year":"2025","journal-title":"J. Phys. Conf. Ser."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"026002","DOI":"10.1117\/1.JMI.7.2.026002","article-title":"Detectability of fluorescent gold nanoparticles under micro-CT and optical projection tomography imaging","volume":"7","author":"Kozomara","year":"2020","journal-title":"J. Med. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"111458","DOI":"10.1016\/j.colsurfb.2020.111458","article-title":"An all-graphene quantum dot F\u00f6rster resonance energy transfer (FRET) probe for ratiometric detection of HE4 ovarian cancer biomarker","volume":"198","author":"Bharathi","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"118119","DOI":"10.1016\/j.trac.2024.118119","article-title":"Recent advancements in biosensors for diagnosis of ovarian cancer: Analytical approaches","volume":"183","author":"Foroozandeh","year":"2024","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1039\/D2LC00874B","article-title":"Microfluidic quantum sensing platform for lab-on-a-chip applications","volume":"22","author":"Allert","year":"2022","journal-title":"Lab Chip"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2307051","DOI":"10.1002\/adma.202307051","article-title":"Microfluidic Platforms for Real-Time In Situ Monitoring of Biomarkers for Cellular Processes","volume":"36","author":"Lou","year":"2023","journal-title":"Adv. Mater."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12014-017-9169-6","article-title":"A multiplex platform for the identification of ovarian cancer biomarkers","volume":"14","author":"Boylan","year":"2017","journal-title":"Clin. Proteom."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1289\/ehp.8284","article-title":"A Toxicologic Review of Quantum Dots: Toxicity Depends on Physicochemical and Environmental Factors","volume":"114","author":"Hardman","year":"2006","journal-title":"Environ. Heal. Perspect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s40001-025-02696-z","article-title":"Promising biomedical applications using superparamagnetic nanoparticles","volume":"30","author":"Fahim","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.nano.2014.01.006","article-title":"Targeted uptake of folic acid-functionalized iron oxide nanoparticles by ovarian cancer cells in the presence but not in the absence of serum","volume":"10","author":"Krais","year":"2014","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_35","first-page":"242","article-title":"Challenges and Future Prospects of Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in Nanomedicine: A Focus on Toxicity, Imaging, and Theranostics","volume":"17","author":"Alvandi","year":"2025","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1369-7021(11)70163-8","article-title":"Magnetite nanoparticles for medical MR imaging","volume":"14","author":"Stephen","year":"2011","journal-title":"Mater. Today"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Vangijzegem, T., Lecomte, V., Ternad, I., Van Leuven, L., Muller, R.N., Stanicki, D., and Laurent, S. (2023). Superparamagnetic Iron Oxide Nanoparticles (SPION): From Fundamentals to State-of-the-Art Innovative Applications for Cancer Therapy. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15010236"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.3402\/nano.v1i0.5358","article-title":"Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION)","volume":"1","author":"Singh","year":"2010","journal-title":"Nano Rev."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Lohani, A.P., Elosta, M., Maksoud, M., and Murshid, N. (2025). Functionalized Carbon Nanotubes: Emerging Nanomaterials for Enhanced Cancer Diagnosis and Imaging. Molecules, 30.","DOI":"10.3390\/molecules30112364"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.msec.2017.02.132","article-title":"Carbon nanotubes: A review of novel strategies for cancer diagnosis and treatment","volume":"76","author":"Sheikhpour","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40820-017-0128-6","article-title":"An Overview of Carbon Nanotubes and Graphene for Biosensing Applications","volume":"9","author":"Zhu","year":"2017","journal-title":"Nano-Micro Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"332001","DOI":"10.1088\/1361-6528\/aac7a4","article-title":"Tumor-on-a-chip platforms for assessing nanoparticle-based cancer therapy","volume":"29","author":"Wang","year":"2018","journal-title":"Nanotechnology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Bai, Y., Xu, T., and Zhang, X. (2020). Graphene-Based Biosensors for Detection of Biomarkers. Micromachines, 11.","DOI":"10.3390\/mi11010060"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Li, C., Che, B., and Deng, L. (2022). Electrochemical Biosensors Based on Carbon Nanomaterials for Diagnosis of Human Respiratory Diseases. Biosensors, 13.","DOI":"10.3390\/bios13010012"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"20200089","DOI":"10.1002\/VIW.20200089","article-title":"Emerging theranostic applications of carbon dots and its variants","volume":"3","author":"Ray","year":"2021","journal-title":"View"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/anie.200502113","article-title":"Polymer Therapeutics: Concepts and Applications","volume":"45","author":"Haag","year":"2006","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: An overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"30544","DOI":"10.1021\/acsomega.4c02258","article-title":"Core-Tunable Dendritic Polymer: A Folate-Guided Theranostic Nanoplatform for Drug Delivery Applications","volume":"9","author":"Koti","year":"2024","journal-title":"ACS Omega"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric Nanoparticles for Drug Delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"(Chezy) Doxil\u00ae\u2014The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1158\/1078-0432.CCR-03-0655","article-title":"Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies","volume":"10","author":"Kim","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"63675","DOI":"10.1155\/JBB\/2006\/63675","article-title":"Targeted Delivery of siRNA","volume":"2006","author":"Oliveira","year":"2006","journal-title":"BioMed Res. Int."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.trac.2008.05.004","article-title":"Nanomaterial-based electrochemical biosensors for medical applications","volume":"27","author":"Kerman","year":"2008","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Sengupta, J., and Hussain, C.M. (2023). CNT and Graphene-Based Transistor Biosensors for Cancer Detection: A Review. Biomolecules, 13.","DOI":"10.3390\/biom13071024"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s40265-019-01158-1","article-title":"Pharmaceutical Management of Ovarian Cancer: Current Status","volume":"79","author":"Markman","year":"2019","journal-title":"Drugs"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: Strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"128ra39","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile","volume":"4","author":"Hrkach","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e000573","DOI":"10.1136\/bmjonc-2024-000573","article-title":"Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): An updated analysis and future perspective","volume":"4","author":"Gabizon","year":"2025","journal-title":"BMJ Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of Cancer Drug Resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2014Developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Bader, A.G. (2012). miR-34\u2014A microRNA replacement therapy is headed to the clinic. Front. Genet., 3.","DOI":"10.3389\/fgene.2012.00120"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","article-title":"Improving cancer immunotherapy through nanotechnology","volume":"19","author":"Goldberg","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0304-8853(99)00088-8","article-title":"Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles","volume":"201","author":"Jordan","year":"1999","journal-title":"J. Magn. Magn. Mater."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2217\/17435889.2.5.681","article-title":"Gold Nanoparticles: Interesting Optical Properties and Recent Applications in Cancer Diagnostics and Therapy","volume":"2","author":"Huang","year":"2007","journal-title":"Nanomedicine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer","volume":"15","author":"Wigler","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/ijgc-00009577-200602001-00011","article-title":"Topotecan and liposomal doxorubicin in recurrent ovarian cancer: Is sequence important?","volume":"16","author":"Dupont","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"TPS8569","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8569","article-title":"ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB\u2013IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC)","volume":"37","author":"Solomon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1188\/10.ONF.137-139","article-title":"Hand-Foot Syndrome Related to Liposomal Doxorubicin","volume":"37","author":"Swenson","year":"2010","journal-title":"Oncol. Nurs. Forum"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00280-015-2737-4","article-title":"A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax\u00ae) in patients with peritoneal malignancies","volume":"75","author":"Williamson","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(26)00462-9","article-title":"Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): A phase 3 randomised controlled trial","volume":"407","author":"Lorusso","year":"2026","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","article-title":"Albumin-bound paclitaxel: A next-generation taxane","volume":"7","author":"Gradishar","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/jcph.304","article-title":"Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel","volume":"54","author":"Chen","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.nano.2016.11.010","article-title":"Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models","volume":"13","author":"Roberts","year":"2016","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2472630318816668","article-title":"siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer","volume":"24","author":"Halbur","year":"2019","journal-title":"JALA J. Assoc. Lab. Autom."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Paris, J.L., and Vallet-Reg\u00ed, M. (2020). Mesoporous Silica Nanoparticles for Co-Delivery of Drugs and Nucleic Acids in Oncology: A Review. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060526"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1016\/j.biomaterials.2010.01.004","article-title":"A bFGF-releasing silk\/PLGA-based biohybrid scaffold for ligament\/tendon tissue engineering using mesenchymal progenitor cells","volume":"31","author":"Sahoo","year":"2010","journal-title":"Biomaterials"},{"key":"ref_84","first-page":"399","article-title":"Survivin as a novel target protein for reducing the proliferation of cancer cells (Review)","volume":"8","author":"Li","year":"2018","journal-title":"Biomed. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.addr.2009.03.009","article-title":"Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Cheng, X., Li, H., Ge, X., Chen, L., Liu, Y., Mao, W., Zhao, B., and Yuan, W.-E. (2020). Tumor-Microenvironment- Responsive Size-Shrinkable Drug-Delivery Nanosystems for Deepened Penetration Into Tumors. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.576420"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s10439-015-1276-9","article-title":"Towards Optimal Design of Cancer Nanomedicines: Multi-stage Nanoparticles for the Treatment of Solid Tumors","volume":"43","author":"Stylianopoulos","year":"2015","journal-title":"Ann. Biomed. Eng."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Brohi, R.D., Wang, L., Talpur, H.S., Wu, D., Khan, F.A., Bhattarai, D., Rehman, Z.-U., Farmanullah, F., and Huo, L.-J. (2017). Toxicity of Nanoparticles on the Reproductive System in Animal Models: A Review. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00606"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13346-020-00740-5","article-title":"Challenges in nanomedicine clinical translation","volume":"10","author":"Metselaar","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"114083","DOI":"10.1016\/j.addr.2021.114083","article-title":"Clinical translation of nanomedicines: Challenges, opportunities, and keys","volume":"181","author":"Younis","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_94","first-page":"742","article-title":"Progress in nanomedicine: Approved and investigational nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/17435889.3.5.703","article-title":"Clearance Properties of Nano-Sized Particles and Molecules as Imaging Agents: Considerations and Caveats","volume":"3","author":"Longmire","year":"2008","journal-title":"Nanomedicine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly lactic-co-glycolic acid (PLGA) As biodegradable controlled drug delivery carrier","volume":"3","author":"Makadia","year":"2011","journal-title":"Polymers"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/CBM-210166","article-title":"MCUR1 is a prognostic biomarker for ovarian cancer patients","volume":"33","author":"Fan","year":"2022","journal-title":"Cancer Biomark."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3892\/ol_00000131","article-title":"Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: A phase II study","volume":"1","author":"Leonardi","year":"2010","journal-title":"Oncol. Lett."},{"key":"ref_99","first-page":"229","article-title":"Pegylated liposomal doxorubicin in ovarian cancer","volume":"1","author":"Green","year":"2006","journal-title":"Int. J. Nanomed."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/cncr.20207","article-title":"Cardiac profiles of liposomal anthracyclines","volume":"100","author":"Theodoulou","year":"2004","journal-title":"Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: A meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"9798","DOI":"10.1038\/s41598-025-94291-9","article-title":"Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer","volume":"15","author":"Ghahremanloo","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1000164","DOI":"10.4172\/2157-7439.1000164","article-title":"Paclitaxel Nano-Delivery Systems: A Comprehensive Review","volume":"4","author":"Ma","year":"2013","journal-title":"J. Nanomed. Nanotechnol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/S0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): An open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Castillo, R.R., Lozano, D., and Vallet-Reg\u00ed, M. (2020). Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12050432"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.nano.2018.04.008","article-title":"Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer","volume":"14","author":"Shahin","year":"2018","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.3390\/ijms15022494","article-title":"Survivin as a Preferential Target for Cancer Therapy","volume":"15","author":"Mobahat","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/IJN.S93496","article-title":"Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene","volume":"11","author":"Luo","year":"2016","journal-title":"Int. J. Nanomed."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Yao, S., Liu, X., Feng, Y., Li, Y., Xiao, X., Han, Y., and Xia, S. (2024). Unveiling the Role of HGF\/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25169101"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1038\/s41598-018-25930-7","article-title":"PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer","volume":"8","author":"Risnayanti","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"100400","DOI":"10.1016\/j.medntd.2025.100400","article-title":"Emerging strategies and multifunctional applications of nanomaterials in modern nanomedicine","volume":"28","author":"Kamaraj","year":"2025","journal-title":"Med. Nov. Technol. Devices"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1158\/0008-5472.CAN-24-1093","article-title":"Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR\u2013ABL\u2013Positive Leukemia","volume":"85","author":"Luo","year":"2024","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"El-Mallul, A., Tomasiuk, R., Pie\u0144kowski, T., Kowalska, M., Hasan, D., Kostrzewa, M., Czerwonka, D., Sado, A., Rogowska, W., and Zubrzycki, I.Z. (2025). Applications of Nanoparticles in the Diagnosis and Treatment of Ovarian Cancer. Nanomaterials, 15.","DOI":"10.3390\/nano15151200"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Bartusik-Aebisher, D., Wilk, I., and Aebisher, D. (2025). Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms. Cancers, 18.","DOI":"10.3390\/cancers18010086"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Sabir, S., Bin Thani, A.S., and Abbas, Q. (2025). Nanotechnology in cancer treatment: Revolutionizing strategies against drug resistance. Front. Bioeng. Biotechnol., 13.","DOI":"10.3389\/fbioe.2025.1548588"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s12672-025-02062-9","article-title":"Nanotechnology-based drug delivery system for the diagnosis and treatment of ovarian cancer","volume":"16","author":"Saripilli","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e2502315","DOI":"10.1002\/smll.202502315","article-title":"Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape","volume":"21","author":"Desai","year":"2025","journal-title":"Small"},{"key":"ref_118","first-page":"100267","article-title":"Nanotechnology and machine learning: A promising confluence for the advancement of precision medicine","volume":"12","author":"Musa","year":"2025","journal-title":"Intell. Med."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1248\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:59:17Z","timestamp":1783677557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":118,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cells15141248"],"URL":"https:\/\/doi.org\/10.3390\/cells15141248","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}